Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3053994 | PMC |
| http://dx.doi.org/10.1073/pnas.1017969108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can there be calm during a cytokine storm? Immune checkpoint pathways affecting the severity of COVID-19 disease.
Front Microbiol
December 2024
Department of Medical Microbiology and Immunology, Medical School, University of Pecs, Pecs, Hungary.
Introduction: The COVID-19 pandemic has become a global health crisis, eliciting varying severity in infected individuals. This study aimed to explore the immune profiles between moderate and severe COVID-19 patients experiencing a cytokine storm and their association with mortality. This study highlights the role of PD-1/PD-L1 and the TIGIT/CD226/CD155/CD112 pathways in COVID-19 patients.
View Article and Find Full Text PDFPVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma.
Leukemia
December 2024
Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
Whole exome sequencing identifies genetic markers of enterovirus susceptibility in East Asians.
Front Microbiol
August 2024
Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Article Synopsis
- The study investigates how the outcomes of acute enterovirus infections vary among individuals, influenced by factors like the immune response, tissue type, and genetic differences.
- It involved whole exome sequencing of blood samples from infected and uninfected individuals to analyze specific genes related to EV entry and replication.
- The researchers identified 118 genetic variants in East Asian populations that might impact susceptibility to enterovirus infections, with plans to use this information to develop a predictive tool for better clinical management.
Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer.
Transl Oncol
August 2024
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil; Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil. Electronic address:
Article Synopsis
- * Immunohistochemical analysis revealed that microsatellite instability (MSI) was rare, and PD-L1 expression was low, showing no link to treatment response, while certain immune checkpoint genes had varied expression levels related to BCG responsiveness.
- * Key findings suggest that PDCD1, CTLA4, TNFRSF14, TIGIT, and CD276 could serve as potential predictive biomarkers for determining BCG treatment outcomes in these patients.
IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
Front Immunol
April 2024
Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Introduction: Sorafenib is currently the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Nevertheless, sorafenib resistance remains a huge challenge in the clinic. Therefore, it is urgent to elucidate the mechanisms underlying sorafenib resistance for developing novel treatment strategies for advanced HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!